In this role, Cheryl will lead Wellcome’s broad programme of discovery research, as well as research related to our three health challenge areas: mental health, infectious diseases, and the health effects of global heating.
Prior to taking up her role at the New York Genome Center, Cheryl held leadership posts at the Howard Hughes Medical Institute, one of the USA’s biggest philanthropic medical research funders.
Cheryl is also a member of the governing boards of the Sainsbury Wellcome Centre for Neural Circuits and Behaviour and of Genome Research Ltd, the parent company of the Wellcome Sanger Institute and Wellcome Genome Campus.
Jeremy Farrar, Director of Wellcome, said: "I’m delighted that Cheryl will be joining us. Among a highly competitive field she stood out as a leader with a great breadth and depth of experience in medical research. She brings a combination of strategic ambition alongside deft operational management, and a record of leading successful innovation.
"She will oversee and develop our new health challenge areas and our crucial discovery research programme, as well as be a key advocate for the positive and inclusive culture we want to nurture throughout the world of research through our role as a funder."
She is expected to take up the post in May 2021.